Altimmune nabs $120.2 million federal contract for nasal spray anthrax vaccine
Gaithersburg-based Altimmune Inc. was awarded a five-year federal contract worth up to $120.2 million for the development of its nasal spray anthrax vaccine candidate.
Under the contract from the U.S. Biomedical Advanced Research and Development Authority, or BARDA, Altimmune was awarded $14.3 million to fund its Phase 1 trial for the vaccine candidate NasoShield. The contract also includes options to receive up to an additional $105.9 million to fund further pr eclinical, clinical and manufacturing…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Tina Reed Source Type: news
More News: Anthrax | Anthrax Vaccine | Contracts | Health | Health Management | Pharmaceuticals | Vaccines